{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1410282679650036610.json","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000378128262"}],"foaf:Person":[{"foaf:name":[{"@language":"en","@value":"Watanabe Kazutoshi"}],"foaf:familyName":[{"@language":"en","@value":"Watanabe"}],"foaf:givenName":[{"@language":"en","@value":"Kazutoshi"}]}],"career":[{"institution":{"notation":[{"@language":"en","@value":"Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1390282679650036608","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.3164/jcbn.17-62"},{"@type":"URI","@value":"https://www.jstage.jst.go.jp/article/jcbn/62/1/62_17-62/_pdf"},{"@type":"PMID","@value":"29371752"},{"@type":"NAID","@value":"130006301233"},{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2019133066"}],"notation":[{"@language":"en","@value":"How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2003555257_aV3q1dDd59apV0V799w4tsNxRFL"},{"@type":"CIA","@value":"130006301233_aV3q1dDd59apV0V799w4tsNxRFL"},{"@type":"CROSSREF","@value":"10.3164/jcbn.17-62_Yftiz4e8c42JW5jyA9BesI1DNhz"},{"@type":"OPENAIRE","@value":"doi_dedup___::4ff6e4b4b732b47cf01956f7286d2e9a_Yftiz4e8c42JW5jyA9BesI1DNhz"}]}